

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Heat shock protein 90 (Hsp90)	<p>Mouse studies identified 3,4-isoxazolidiamide-based Hsp90 inhibitors that could help treat cancer. In a mouse xenograft model of squamous cell carcinoma, a lead Hsp90 inhibitor produced decreases in tumor growth comparable to those created by the existing Hsp90 inhibitor AUY922. Next steps include evaluating members of the series against other tumor cell lines and determining their pharmacokinetics.</p> <p>AUY922, a resorcinol-based Hsp90 inhibitor from Vernalis plc and Novartis AG, is in Phase II testing for non-small cell lung cancer (NSCLC) and hematologic malignancies.</p> <p>At least 12 other companies have Hsp90 inhibitors in Phase II trials or earlier for cancer.</p> <p>SciBX 4(47); doi:10.1038/scibx.2011.1318 Published online Dec. 8, 2011</p>	<p>Patented; available for licensing from Sigma-Tau S.p.A., a subsidiary of Sigma-Tau Group</p> <p>Contact: Walter Cabri, Sigma-Tau S.p.A., Rome, Italy e-mail: walter.cabri@sigma-tau.it</p>	<p>Baruchello, R. <i>et al. J. Med. Chem.</i>; published online Nov. 9, 2011; doi:10.1021/jm201155e</p> <p>Contact: Giuseppina Grisolia, Sigma-Tau S.p.A., Rome, Italy e-mail: giuseppe.giannini@sigma-tau.it</p> <p>Contact: Stefania Mangiola, University of Ferrara, Ferrara, Italy e-mail: smd@unife.it</p>